|
Medtronic received information regarding a catheter.It was reported that the ventriculoperitoneal shunt was intended to drain cerebrospinal fluid in a patient with hydrocephalus, relieve the symptoms of hydrocephalus, and reduce intracranial pressure.Its clinical indications included obstructive hydrocephalus, communicating hydrocephalus, and other conditions requiring cerebrospinal fluid diversion.The patient had a clinical indication for ventriculoperitoneal shunt surgery because of hydrocephalus.On (b)(6) 2026, cranioplasty and ventriculoperitoneal shunt surgery were performed under general anesthesia, and the shunt was implanted.A rejection reaction/inflammation could have occurred after implantation.The patient's intracranial inflammatory response was controlled, cerebrospinal fluid inflammatory indicators were monitored dynamically, and the medical device adverse event was reported.Date of improvement was (b)(6) 2026.
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|